CNTB
Connect Biopharma Holdings Ltd
$2.12
+0.95%
$133.5M
No data for this timeframe.
Vol
Market Cap$133.5M
Cap SizeMicro Cap
Analyst ConsensusStrong Buy (92%)
Inst. Holders7 funds
Inst. Value$245.3K
Inst. Activity1 buys / 1 sells
Insider Activity1B / 0S
Insider Net $$4.0M
SEC Reports4
Press Releases1
Recent Activity
May 18, 2026
earnings_calendar
CNTB Q1 2026 Earnings Scheduled — 2026-05-18
May 12, 2026
SEC
Connect Biopharma reported Q1 2026 results with a net loss of $19.4M ($0.34/share), widening from a $10.3M loss ($0.19/s
8-K — Impact 4/10
May 12, 2026
SEC
Connect Biopharma reported Q1 2026 net loss of $0.34 per share, significantly wider than the consensus estimate of -$0.2
PRESS-RELEASE — Impact 6/10
Apr 23, 2026
SEC
Connect Biopharma announced that the independent Data Monitoring Committee (DMC) completed its interim analysis of effic
8-K — Impact 7/10
Mar 31, 2026
Insider
LIU JEAN I was granted 5,061 shares
Director
Mar 31, 2026
Insider
Xanthopoulos Kleanthis Gabriel was granted 2,816 shares
Director
Mar 31, 2026
Insider
Huang James bought 1,160,000 shares
Director @ $3.45 ($4.0M)
Inst.
RENAISSANCE TECHNOLOGIES LLC — ADD
143,700 shares ($140.8K)
Price Targets
$7.07
+233.6% upside
Strong Buy
Current $2.12
Low $4.00
Median $7.00
High $10.00
7 analysts
$4.00
$10.00
Analyst Ratings
4Strong Buy
8Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 26, 2026 | Canaccord Genuity | INITIATE | Buy |
| May 21, 2026 | Cantor Fitzgerald | INITIATE | Overweight |
| Apr 1, 2026 | BTIG | REITERATE | Buy → Buy |
| Mar 31, 2026 | BTIG | REITERATE | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.31 ▼ -18.2% | $-0.33 — $-0.29 | 6 | |
| Next Q | $-0.26 ▼ -18.6% | $-0.33 — $-0.16 | 18% YoY | 6 |
| Current FY | $-1.06 ▼ -26.1% | $-1.14 — $-0.80 | -6% YoY | 5 |
| Next FY | $-1.05 ▼ -2.1% | $-1.80 — $-0.50 | 5% YoY | 7 |
Latest Reports
NEUTRAL
8-K
4/10
Connect Biopharma reported Q1 2026 results with a net loss of $19.4M ($0.34/share), widening from a $10.3M loss ($0.19/s
May 12, 2026
BEARISH
PRESS-RELEASE
6/10
Connect Biopharma reported Q1 2026 net loss of $0.34 per share, significantly wider than the consensus estimate of -$0.2
May 12, 2026
NEUTRAL
Press
5/10
Connect Biopharma announced a private placement of 6,130,000 ordinary shares at $3.25 per share, raising approximately $
Mar 30, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | $140.8K | ADD |
| CITADEL ADVISORS LLC | $62.0K | — |
| ROYAL BANK OF CANADA | $40.0K | TRIM |
| RHUMBLINE ADVISERS | $2.4K | NEAR_EXIT |
| MORGAN STANLEY | $98.00 | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Mar 31, 2026 | LIU JEAN | A | $0.00 |
| Mar 31, 2026 | Xanthopoulos Kleanthis | A | $0.00 |
| Mar 31, 2026 | Huang James | BUY | $4.0M |
7 institutional holders with $245.3K total value (268,604 shares) as of 2025-Q2. Top holders: RENAISSANCE, CITADEL, ROYAL.
Top Institutional Holders — 2025-Q2
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | RENAISSANCE TECHNOLOGIES LLC | 143,700 | $140.8K | 57.4% | ADD +25.2% |
| 2 | CITADEL ADVISORS LLC | 61,992 | $62.0K | 25.3% | — |
| 3 | ROYAL BANK OF CANADA | 40,400 | $40.0K | 16.3% | TRIM -49.8% |
| 4 | RHUMBLINE ADVISERS | 2,370 | $2.4K | 1.0% | NEAR_EXIT -75.1% |
| 5 | MORGAN STANLEY | 100 | $98.00 | 0.0% | — |
| 6 | UBS Group AG | 42 | $41.00 | 0.0% | NEAR_EXIT -99.5% |
| 7 | COMMONWEALTH EQUITY SERVICES, LLC | 20,000 | $20.00 | 0.0% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | ADD | 114,800 | 143,700 | +25.2% | $140.8K | 2025-Q2 |
| UBS Group AG | NEAR_EXIT | 8,739 | 42 | -99.5% | $41.00 | 2025-Q2 |
| ROYAL BANK OF CANADA | TRIM | 80,400 | 40,400 | -49.8% | $22.0K | 2025-Q1 |
| UBS Group AG | ADD | 4,733 | 8,739 | +84.6% | $4.8K | 2025-Q1 |
| RHUMBLINE ADVISERS | NEAR_EXIT | 9,500 | 2,370 | -75.1% | $1.3K | 2025-Q1 |
| ROYAL BANK OF CANADA | DOUBLED | 30,600 | 80,400 | +162.7% | $111.0K | 2024-Q4 |
| ROYAL BANK OF CANADA | DOUBLED | 12,700 | 30,600 | +140.9% | $44.0K | 2024-Q3 |
3 unique insiders with 3 transactions. Net insider value: $4.0M ($4.0M bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Mar 31, 2026 | LIU JEAN I | Director | AWARD | 5,061 | — | — |
| Mar 31, 2026 | Xanthopoulos Kleanthis Gabriel | Director | AWARD | 2,816 | — | — |
| Mar 31, 2026 | Huang James | Director | BUY | 1,160,000 | $3.45 | $4.0M |
4 SEC filing reports analyzed. Sentiment: 1 bullish, 1 bearish, 1 mixed, 1 neutral. Avg impact: 5.8/10.
NEUTRAL
8-K
4/10
Connect Biopharma reported Q1 2026 results with a net loss of $19.4M ($0.34/share), widening from a
May 12, 2026
BEARISH
PRESS-RELEASE
6/10
Connect Biopharma reported Q1 2026 net loss of $0.34 per share, significantly wider than the consens
May 12, 2026
BULLISH
8-K
7/10
Connect Biopharma announced that the independent Data Monitoring Committee (DMC) completed its inter
Apr 23, 2026
MIXED
8-K
6/10
Connect Biopharma reported full-year 2025 financial results with a net loss of $55.5 million ($1.00
Apr 21, 2026
Current analyst consensus: Strong Buy (92% buy). Based on 13 analysts: 4 strong buy, 8 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$7.07 mean target
+233.6% upside
Strong Buy (1.00)
$4.00 Low
$10.00 High
| Metric | Value |
|---|---|
| Current Price | $2.12 |
| Target Low | $4.00 |
| Target Mean | $7.07 |
| Target Median | $7.00 |
| Target High | $10.00 |
| # Analysts | 7 |
| Recommendation | Strong Buy (1.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.31 | $-0.33 | $-0.29 | — | -18.2% | 1↑ 0↓ | $0.0B | -43.7% | 6 |
| Next Q 2026-09-30 |
$-0.26 | $-0.33 | $-0.16 | 17.7% | -18.6% | 1↑ 0↓ | $0.0B | 70.4% | 6 |
| Current FY 2026-12-31 |
$-1.06 | $-1.14 | $-0.80 | -6.2% | -26.1% | 4↑ 0↓ | $0.0B | 8811.0% | 5 |
| Next FY 2027-12-31 |
$-1.05 | $-1.80 | $-0.50 | 5.0% | -2.1% | 2↑ 1↓ | $0.1B | 88.4% | 7 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.313 | |
| 7d ago | $-0.313 | |
| 30d ago | $-0.265 | -0.048 |
| 60d ago | $-0.250 | -0.063 |
| 90d ago | $-0.290 | -0.023 |
3 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 2 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 26, 2026 | Canaccord Genuity | INITIATE | — | Buy |
| May 21, 2026 | Cantor Fitzgerald | INITIATE | — | Overweight |
| Apr 1, 2026 | BTIG | REITERATE | Buy | Buy |
| Mar 31, 2026 | BTIG | REITERATE | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 4 | 8 | 1 | 0 | 0 | 92% | |
| May 1, 2026 | 4 | 6 | 1 | 0 | 0 | 91% | |
| Apr 1, 2026 | 4 | 6 | 1 | 0 | 0 | 91% | |
| Mar 1, 2026 | 4 | 6 | 1 | 0 | 0 | 91% | |
| Feb 1, 2026 | 4 | 6 | 1 | 0 | 0 | 91% | |
| Jan 1, 2026 | 4 | 6 | 1 | 0 | 0 | 91% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 18, 2026
earnings_calendar
CNTB Q1 2026 Earnings Scheduled — 2026-05-18
May 12, 2026
other
Connect Biopharma to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference
<p>SAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect or the Company), a clin
May 12, 2026
earnings
Connect Biopharma Reports First Quarter 2026 Financial Results and Provides Business Update
<p align="center"><em>– Phase 2 Seabreeze STAT studies for acute exacerbations in asthma and COPD continuing as planned based on independent DMC revie
Mar 31, 2026
earnings
Connect Biopharma Reports 2025 Full-Year Financial Results and Provides Business Update
<p align="center"><em>– Released positive topline data from Phase 1 study of IV rademikibart in patients with asthma or COPD –</em><br></p>
Mar 30, 2026
offering
Connect Biopharma Announces $20.2 Million Private Placement Financing
<p align="center"><em>Funding from new and existing investors extends anticipated cash runway into the second half of 2027</em></p>
Mar 30, 2026
other
Rademikibart Demonstrates Best-in-Class Potential in Phase 3 Atopic Dermatitis Study
<p align="center"><em>– Rademikibart achieved rapid, durable efficacy results across all key endpoints through 52 weeks, with near</em><em>‑</em><em>m
Mar 30, 2026
fda
Connect Biopharma Announces Positive Topline Data from its Phase 1 Study of Intravenous (IV) Rademikibart in Patients with Asthma or COPD
<p align="center"><em>– Rademikibart administered as a single 300 mg 2-minute IV push to asthma and chronic obstructive pulmonary disease </em>(<em>CO
Mar 3, 2026
other
Connect Biopharma to Present at the Leerink Partners Global Healthcare Conference
<p>SAN DIEGO, March 03, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma”, “Connect”, or the “Company”